(Q35883830)

English

The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression

scientific article published in June 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

1 reference

Europe PubMed Central

The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

multiple myeloma

1 reference

based on heuristic

inferred from title

Xavier Mariette

2

object named as

Xavier Mariette

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

author name string

Sophie Roux

1

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

publication date

1 June 2004

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

45

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

1111-1118

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Myeloma bone disease

1 reference

https://api.crossref.org/works/10.1080%2F10428194310001593193

21 January 2018

RANK ligand and osteoprotegerin in myeloma bone disease.

1 reference

https://api.crossref.org/works/10.1080%2F10428194310001593193

21 January 2018

Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease

1 reference

https://api.crossref.org/works/10.1080%2F10428194310001593193

21 January 2018

Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma

1 reference

https://api.crossref.org/works/10.1080%2F10428194310001593193

21 January 2018

Role of the bone marrow microenvironment in multiple myeloma

1 reference

https://api.crossref.org/works/10.1080%2F10428194310001593193

21 January 2018

TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy

1 reference

https://api.crossref.org/works/10.1080%2F10428194310001593193

21 January 2018

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1080%2F10428194310001593193

21 January 2018

Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease

1 reference

https://api.crossref.org/works/10.1080%2F10428194310001593193

21 January 2018

Interleukin-4 Reversibly Inhibits Osteoclastogenesis via Inhibition of NF-κB and Mitogen-activated Protein Kinase Signaling

1 reference

https://api.crossref.org/works/10.1080%2F10428194310001593193

21 January 2018

Identifiers

10.1080/10428194310001593193

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35883830&oldid=1604009653"